Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease

January 25, 2021 updated by: Katrine Sværke, Bispebjerg Hospital

The Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease

The current study adresses the effect of two different computer-based cognitive trianing programmes on attention and executive functions in patients with Parkinson's disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The current study adresses the effect of two different computer-based cognitive training programmes (Brain+ Evolution and Scientific Brain Training PRO) on attention and executive functions in patients with Parkinson's disease. The patients are assigned to one of three groups. Two training groups with each their programme, and a control Group. The training groups will train at home for 8 weeks with follow-ups every second week. The control group will not train at home, but will also receive a follow-up with computer-based stimuli (computerized Card game) every second week, to minimize the possibility that a possible effect is due to the follow-up's with a professional, and not due to the computer training at home.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
    • Region Hovedstaden
      • Copenhagen, Region Hovedstaden, Denmark, 2400
        • Bispebjerg Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with Parkinson's disease AND
  • Montreal cognitive assesment (MOCA)-score between 22-28
  • Motorically cabable of using an iPad
  • Not receiving antipsychotic medicine
  • No comorbid diseases which might influence the level of executive functioning, for an example ADHD or acquired brain damage

Exclusion Criteria:

  • People without Parkinson's disease
  • Parkinson's patients not included in the above inclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Brain+ Evolution

Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.

Computer-based cognitive training.
Device: Computer-based cognitive training
Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
Experimental: Scientific Brain Training PRO

Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.

Computer-based cognitive training.
Device: Computer-based cognitive training
Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
No Intervention: Control group
This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SDMT
Time Frame: 2 minutes
Symbol digit modalities test, neuropsychological test of processing speed
2 minutes
PDQ-39
Time Frame: 20 minutes
Parkinson's disease questionnaire; daily functioning and well-being in Parkinson's disease
20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HADS
Time Frame: 10 minutes
Hospital anxiety and depression screening
10 minutes
Digit span
Time Frame: 10 minutes
Digit span Wais-IV; Working memory
10 minutes
Verbal fluency
Time Frame: 3 minutes
S-Words, animal-names and A/F-words
3 minutes
Stroop colour/word test
Time Frame: 3 minutes
Stroop colour/Word test, respone inhibition
3 minutes
Trail Making A and B
Time Frame: 5 minutes
Trail Making A and B, cognitive flexibility
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bispebjerg Hospital

Investigators

  • Study Director: Annemette Løkkegaard, Ph.d., doctor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2017

Primary Completion (Actual)

February 29, 2020

Study Completion (Actual)

June 30, 2020

Study Registration Dates

First Submitted

September 14, 2017

First Submitted That Met QC Criteria

September 14, 2017

First Posted (Actual)

September 18, 2017

Study Record Updates

Last Update Posted (Actual)

January 26, 2021

Last Update Submitted That Met QC Criteria

January 25, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • H-17000220

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Computer-based cognitive training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe